These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 33155957)

  • 21. Triple antithrombotic therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation.
    Kang DO; Yu CW; Kim HD; Cho JY; Joo HJ; Choi RK; Park JS; Lee HJ; Kim JS; Park JH; Hong SJ; Lim DS
    Coron Artery Dis; 2015 Aug; 26(5):372-80. PubMed ID: 25768244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Warfarin and Antiplatelet Therapy Versus Warfarin Alone for Treating Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement.
    Abdul-Jawad Altisent O; Durand E; Muñoz-García AJ; Nombela-Franco L; Cheema A; Kefer J; Gutierrez E; Benítez LM; Amat-Santos IJ; Serra V; Eltchaninoff H; Alnasser SM; Elízaga J; Dager A; García Del Blanco B; Ortas-Nadal Mdel R; Marsal JR; Campelo-Parada F; Regueiro A; Del Trigo M; Dumont E; Puri R; Rodés-Cabau J
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1706-17. PubMed ID: 27539691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.
    Lopes RD; Heizer G; Aronson R; Vora AN; Massaro T; Mehran R; Goodman SG; Windecker S; Darius H; Li J; Averkov O; Bahit MC; Berwanger O; Budaj A; Hijazi Z; Parkhomenko A; Sinnaeve P; Storey RF; Thiele H; Vinereanu D; Granger CB; Alexander JH;
    N Engl J Med; 2019 Apr; 380(16):1509-1524. PubMed ID: 30883055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial.
    Vranckx P; Valgimigli M; Eckardt L; Lewalter T; Unikas R; Marin F; Schiele F; Laeis P; Reimitz PE; Smolnik R; Zierhut W; Tijssen J; Goette A
    Eur Heart J; 2020 Dec; 41(47):4497-4504. PubMed ID: 32860041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: design of the MUSICA-2 randomized trial.
    Sambola A; Montoro JB; Del Blanco BG; Llavero N; Barrabés JA; Alfonso F; Bueno H; Cequier A; Serra A; Zueco J; Sabaté M; Rodríguez-Leor O; García-Dorado D
    Am Heart J; 2013 Oct; 166(4):669-75. PubMed ID: 24093846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use and Outcomes of Triple Antithrombotic Therapy with Non-Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
    Casamira N; García-Camarero T; Montoro-Ronsano JB; Veiga G; Del Blanco BG; De La Torre JM; Gordon B; García-Dorado D; Sambola A
    Am J Med Sci; 2019 Aug; 358(2):95-103. PubMed ID: 31176420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rivaroxaban in Patients With Atrial Fibrillation Who Underwent Percutaneous Coronary Intervention in Clinical Practice.
    Zeymer U; Toelg R; Wienbergen H; Hobbach HP; Cuneo A; Bekeredjian R; Ritter O; Hailer B; Hertting K; Hennersdorf M; Scholtz W; Lanzer P; Mudra H; Schwefer M; Schwimmbeck PL; Liebetrau C; Thiele H; Claas C; Riemer T; Zahn R
    Am J Cardiol; 2023 Feb; 189():31-37. PubMed ID: 36493580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
    Mishra A; Singh M; Acker WW; Kamboj S; Sporn D; Stapleton D; Kaluski E
    J Cardiovasc Pharmacol; 2019 Aug; 74(2):82-90. PubMed ID: 31306367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes.
    Maeng M; Steg PG; Bhatt DL; Hohnloser SH; Nordaby M; Miede C; Kimura T; Lip GYH; Oldgren J; Ten Berg JM; Cannon CP;
    JACC Cardiovasc Interv; 2019 Dec; 12(23):2346-2355. PubMed ID: 31806216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive performance of different bleeding risk scores in patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary intervention.
    Lyu SQ; Zhu J; Wang J; Wu S; Zhang H; Shao XH; Yang YM
    Platelets; 2022 Aug; 33(6):900-910. PubMed ID: 35103582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antithrombotic treatment beyond 1 year after percutaneous coronary intervention in patients with atrial fibrillation.
    Jensen T; Thrane PG; Olesen KKW; Würtz M; Mortensen MB; Gyldenkerne C; Thim T; Nørgaard BL; Jensen JM; Kristensen SD; Nielsen JC; Eikelboom JW; Maeng M
    Eur Heart J Cardiovasc Pharmacother; 2023 Apr; 9(3):208-219. PubMed ID: 36269306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atrial fibrillation in acute coronary syndrome: patient characteristics and appropriate utilisation of anti-thrombotic therapy in New Zealand (ANZACS-QI 39).
    Ho CY; Nunn C; White J; Kerr A; Lee M
    N Z Med J; 2020 Jul; 133(1519):41-54. PubMed ID: 32777794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atrial Fibrillation and Coronary Artery Disease: A Long-Term Perspective on the Need for Combined Antithrombotic Therapy.
    Fanaroff AC; Li S; Marquis-Gravel G; Giri J; Lopes RD; Piccini JP; Wang TY
    Circ Cardiovasc Interv; 2021 Dec; 14(12):e011232. PubMed ID: 34932388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: in-hospital-data from the Atrial Fibrillation undergoing Coronary Artery Stenting study.
    Schlitt A; Rubboli A; Lip GY; Lahtela H; Valencia J; Karjalainen PP; Weber M; Laine M; Kirchhof P; Niemelä M; Vikman S; Buerke M; Airaksinen KE;
    Catheter Cardiovasc Interv; 2013 Dec; 82(7):E864-70. PubMed ID: 23765437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post-discharge antithrombotic management and clinical outcomes of patients with new-onset or pre-existing atrial fibrillation and acute coronary syndromes undergoing coronary stenting: Follow-up data of the MATADOR-PCI study.
    De Luca L; Di Lenarda A; Rubboli A; Bolognese L; Gonzini L; Fortuni F; Navazio A; Poletti F; Ledda A; Urbinati S; Gabrielli D; Gulizia MM;
    Eur J Intern Med; 2021 Jun; 88():28-34. PubMed ID: 33838988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy and safety of new oral anticoagulants as part of triple antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome. Data from an observational study].
    Sycheva NA; Koroleva LY; Nosov VP; Kovaleva GV; Paikova NN; Volkova AT; Kisel AM
    Kardiologiia; 2020 Aug; 60(7):53-63. PubMed ID: 33155941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Major bleeding complications related to combined antithrombotic therapy in atrial fibrillation patients 12 months after coronary artery stenting.
    Kawai H; Watanabe E; Yamamoto M; Harigaya H; Sano K; Takatsu H; Muramatsu T; Naruse H; Sobue Y; Motoyama S; Sarai M; Takahashi H; Arakawa T; Kan S; Sugiura A; Murohara T; Ozaki Y
    J Cardiol; 2015 Mar; 65(3):197-202. PubMed ID: 25266323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.
    Ten Berg JM; de Veer A; Oldgren J; Steg PG; Zateyshchikov DA; Jansky P; Seung KB; Hohnloser SH; Lip GYH; Nordaby M; Kleine E; Bhatt DL; Cannon CP;
    JACC Cardiovasc Interv; 2019 Dec; 12(23):2331-2341. PubMed ID: 31806214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safe and Efficacious Use of 1-Month Triple Therapy in Patients with Atrial Fibrillation and High Bleeding Risk Undergoing PCI.
    Sambola A; Bueno H; Miranda B; Hernandez AV; Limeres J; Del Blanco BG; García-Dorado D
    Cardiovasc Drugs Ther; 2019 Aug; 33(4):425-433. PubMed ID: 31332653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
    Vranckx P; Valgimigli M; Eckardt L; Tijssen J; Lewalter T; Gargiulo G; Batushkin V; Campo G; Lysak Z; Vakaliuk I; Milewski K; Laeis P; Reimitz PE; Smolnik R; Zierhut W; Goette A
    Lancet; 2019 Oct; 394(10206):1335-1343. PubMed ID: 31492505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.